drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An intravenous bispecific T‑cell–redirecting antibody (MUC16×CD3) that binds MUC16 on tumor cells and CD3 on T cells to recruit and activate cytotoxic T cells, inducing tumor cell lysis.
nci_thesaurus_concept_id
C153129
nci_thesaurus_preferred_term
Ubamatamab
nci_thesaurus_definition
A bispecific, human monoclonal antibody with potential antineoplastic activity. REGN4018 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen that is part of the T cell receptor complex, and one for human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a member of the mucin family of glycoproteins that is overexpressed by several epithelial cancers, including ovarian cancer. Upon administration, ubamatamab binds to both T-cells and MUC16-expressing tumor cells, which cross-links the T-cells to the tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells.
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
A bispecific MUC16×CD3 T‑cell–redirecting antibody that binds MUC16 on tumor cells and CD3 on T cells, crosslinking and activating cytotoxic T cells to drive targeted lysis of MUC16‑expressing cancer cells.
drug_name
Ubamatamab
nct_id_drug_ref
NCT06444880